LAURUS Labs
Chemistry for Better Living

July 24, 2026

To	To
The Corporate Relations Department **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 **Code: 540222**	**The Listing Department** **National Stock Exchange of India Ltd.,** Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 **Code: LAURUSLABS**

Dear Sir / Madam,

Sub: <u>Press Release on the Financial Results for the quarter ended June 30, 2026</u>

Please find enclosed the Press Release on the Unaudited Financial Results of the Company for the quarter ended June 30, 2026.

This is for your information and records.

Thanking you,

Yours sincerely,
For **Laurus Labs Limited**
VENKATESWAR REDDY GOGIREDDY
Digitally signed by VENKATESWAR REDDY GOGIREDDY
Date: 2026.07.24 14:54:55 +05'30'
G. Venkateswar Reddy
Company Secretary & Compliance Officer

Encl: A/a

LAURUS Labs
Chemistry for Better Living

Press Release

FOR IMMEDIATE RELEASE

24 JULY, 2026

Laurus Labs Announces Q1 FY27 Results

Revenue at ₹ 2,026 Cr; EBITDA at ₹ 644 Cr, 31.8% margins

Hyderabad, July 24, 2026: Laurus Labs Ltd. (**Laurus BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01028**), a leading research and development driven pharmaceutical and biotech company in India announces its Q1 FY27 results.

Financial Summary

[₹ Crore] except EPS amounts	1Q FY27	1Q FY26	Y-o-Y
Revenue	2,026	1,570	29%
Gross Margins	62.7%	59.4%	3.3%
EBITDA	644	389	66%
EBITDA Margins	31.8%	24.8%	7.0%
PBT	481	224	115%
Net Profit	368	163	126%
EPS (Diluted)	6.8	3.0	127%

Dr. Satyanarayana Chava, Founder & Chief Executive Officer commented;

"Laurus has delivered record quarterly Revenue with expanded profitability and continued its portfolio transformation. This was driven by growing commercial deliveries within CDMO and continued strength in Affordable Medicines portfolio. During the quarter, we strengthened our Integrated offerings, niche capabilities that matter most to our clients.

We also achieved important milestones, including agreement to in-license two Antibody Drug Conjugates (ADCs) and securing final handover of new land parcel, reinforcing our long-term growth strategy.

I am pleased with our progress, and excited about next wave of business opportunities driving confidence in our ability to deliver sustained growth and value creation."

Corporate Office
Plot No. 103, Road No.1, Jubilee Hills, Hyderabad 500033, Telangana, India
T +91 40 6659 4333, 2342 0500/501 **F** +91 40 6659 4320

Registered Office
Laurus Enclave, Plot Office 01, E.Bonangi Village, Parawada Mandal, Anakapalli District – 531021, Andra Pradesh, India
CIN : L24239AP2005PLC047518, **T** +91 891 682 1101, 1102, **F** +91 891 682 1103, E info@lauruslabs.com, **W** lauruslabs.com

V V Ravi Kumar, Executive Director & Chief Financial Officer commented;

"We delivered a strong operating performance in Q1 despite challenging macroeconomic volatility. We are pleased to see sustained momentum across both CDMO and Affordable Medicine division. We have achieved revenue of ₹ 2,026 Cr, representing 29% growth and EBITDA of ₹ 644 Cr, representing 66% growth. The EBITDA margins were strong and consistently improved at 31.8%, supported by improvement in capacity utilization and operating leverage. Gross margins improved by over 3% pts to 62.7% due to favorable segment mix.

Our commercial and operational execution continues to enable us to generate strong results and we are continuing on our key CAPEX program to drive near and long term growth."

Divisional Revenue Performance

[₹ Crore]	1Q FY27	1Q FY26	Y-o-Y
CDMO	**870**	**522**	**67%**
Small molecules	835	493	69%
Bio	35	29	21%
Affordable Medicines (Generics)	**1,156**	**1,048**	**10%**
API	654	637	3%
FDF	502	411	22%
Total Revenue	**2,026**	**1,570**	**29%**
ARV Revenue*	669	647	3%

* Includes API and Formulation (FDF) combined revenue

Summary Highlights:

- Continued strong Q1 performance; ₹ 2,026 Cr Revenue and 29% revenue growth
- Strong growth in CDMO driven by commercial projects, and steady momentum in Affordable medicines
- ₹ 644 Cr EBITDA resulted in a margin of 31.8%, increased by 7.0% pts, contributed by enhanced CDMO revenue and operational leverage
- Gross margins expansion of over 3% pts to 62.7% on healthy business mix
- Continued investment into manufacturing network expansion and niche capabilities with CAPEX at 19% of sales
- Planned Capex increase over FY27 & FY28 well on track to support growth projects across Small molecule (Human & Animal health), Fermentation, Peptides, Gene therapy and Antibody Drug conjugates

Divisional Highlights:

CDMO – Small molecules

- CDMO business reported revenue of ₹ 835 Cr, during Q1FY27; increased by 69% mainly driven by growth in late-stage clinical and commercial API supplies and ramp-up of the growth projects

- Continued focus on new modalities with key partners and fully integrated projects
- Advancing commercial peptides manufacturing capability based on customer demand
- Pipeline momentum remained healthy: >125 Active projects across Human health, Animal health and Crop science
- We are continuing CAPEX in large-scale API & Fermentation capacity in Vizag

BIO – Large molecules

- Bio business reported revenue of ₹ 35 Cr, during Q1FY27; increased by 21%.
- Strong traction in the enzymatic technology application across small molecule clinical and commercial API projects
- Expect fermentation facility to be commissioned by Q3FY27

Affordable Medicines (Generics)

- Affordable Medicines division reported revenue of ₹ 1,156 Cr, during Q1FY27, increased by 10%
- Growth driven by steady ARV, established product volume growth and new launches in the US
- Maintained consistent deliveries track record amid continuing global supply chain issues
- Capacity expansion and resource allocation going as per plan with focus on integrated CMO supplies
- KRKA JV update: FDF site progress fully on track. Phase-I production blocks to be opened in mid-2027 focusing on High Potent and General OSD capability
- Product filings update:
  - DMF filings: Cumulatively, 92 DMFs filed till date
  - Developed market FDF filings: 2 product dossiers filed in Q1FY27. Cumulatively, 96 products filed till date

R&D and Other Highlights:

- Total R&D investments including capex R&D for the quarter was ₹ 118 Cr* (5.8% of Revenue), increased significantly by 74% Y/Y due to development efforts toward building Advanced Biologics infrastructure (Gene Therapy/Antibody Drug Conjugates)
- Laurus Labs in-licensed two ADC assets from Aarvik Therapeutics for development and commercialization for India markets

Quality and ESG Highlights:

- We completed 24 Quality audits in Q1. Company has successfully passed audit inspections without critical findings
- Science Based Targets initiative (SBTi) has approved Laurus Labs near-term science-based emissions reduction targets, marking important milestone in our sustainable journey

LAURUS Labs
Chemistry for Better Living

Earnings Conference Call

The company will organize a conference call on Friday, July 24, 2026 - 5:00 pm IST to discuss Q1 FY27 results followed by an interactive Q&A session from participants. All participants may join the call by dialing below numbers OR by using Diamond Pass link

Conference Dial-in	
Universal Dial-In	+91 22 6280 1384
India Local access Number	+91 22 7115 8285
Singapore	+800 101 2045
Hong Kong	+800 964 448
USA	+1 866 746 2133
UK	+0 808 101 1573
Express Join with Diamond Pass	**Click here to register**

Transcript of the conference call will be available on the Company's website: www.lauruslabs.com

END

Media Relations

Karthik C
T +91 40 3980 4380 | 9030088669
mediarelations@lauruslabs.com

Investors Relations

Vivek Kumar
T +91 40 3980 4366
investorrelations@lauruslabs.com

About Laurus Labs

Laurus Labs is a research-driven pharmaceutical and biotechnology company committed to improving global health. It holds a leadership position in developing and manufacturing select Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF) across anti-retroviral, oncology, cardiovascular, and gastro therapeutics. With strong backward integration and stringent quality standards, Laurus has built a solid reputation for high-quality, innovative solutions.

The company offers end-to-end Contract Development and Manufacturing Organization (CDMO) services, supporting innovators from early-stage development to commercial production. Laurus employs over 8,126 people, including 3,134+ scientists, and operates 15 facilities approved by global regulators like the USFDA, WHO, EMA, and more. Its “Smart and Green” chemistry approach drives sustainable manufacturing and operational excellence.

Laurus Labs generated ₹6,813 crore in revenue in FY2026 and is listed on the BSE and NSE. The company is a certified Great Place to Work and holds a “BBB” MSCI ESG rating, reflecting its commitment to transparency, integrity, and ESG principles. It is widely recognized for upholding environmental stewardship and ethical business practices.

Expanding beyond small molecules, Laurus is enhancing its capabilities in biotechnology, large molecules, cell, and gene therapies. Its diversified offerings span human and animal health APIs, intermediates, crop science, and specialty ingredients for nutrition and cosmetics. Guided by the principle “Chemistry for Better Living,” Laurus remains dedicated to advancing science for better global health outcomes. Corporate Identification No: L24239AP2005PLC047518.

For more information visit **www.lauruslabs.com**

Follow @ Laurus Labs on **LinkedIn** | **Twitter** | **Facebook** | **Instagram**

Disclaimer

Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.